FVIII Mimetics in Hemophilia: Comparing Emicizumab, Mim8, and NXT007 – Key Insights from BIC Meeting
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”FVIII mimetics – How different are these products? Fascinating insights from Peter Lenting at the BIC meeting on the evolving landscape of FVIII-mimetic therapies․
Emicizumab – The established pioneer with proven clinical efficacy, stimulating FIXa activity ~10-fold less than FVIIIa but effectively promoting thrombin generation and fibrin formation
Mim8 – Next-generation optimization with >20,000-fold increase in FIXa proteolytic activity and 15-fold higher potency vs emicizumab in vitro
NXT007 – Enhanced affinity through novel light chain engineering, showing 30-40 fold higher affinity for FX/FXa with improved ternary complex formation
Different epitopes, different mechanisms: While all target the FIXa-FX interaction, each product has unique binding sites and kinetic properties. Mim8’s distinct epitope includes loop 333-338 (FVIIIa binding site), potentially explaining its enhanced cofactor activity.
Clinical implications beyond haemophilia A: FVIII mimetics show promise for various bleeding disorders:
– Acquired hemophilia A – bypassing FVIII inhibitors effectively
– Type 3 von Willebrand disease – addressing the associated FVIII deficiency component
– Patients with alloantibodies to VWF or FVIII
Note: Inno8 was not part of this session, as this innovative oral development was presented in a dedicated session earlier at the meeting by Jan Astermark.”
Stay updated with Hemostasis Today.
-
Oct 3, 2025, 07:53Pancytopenia in Pregnancy: A Time-Critical Hematological Emergency
-
Oct 2, 2025, 14:12Helen McPherson at ISFP-IFRS 2025: Fibrin Clot Structure and Function Modulation by Targeting Fibrinogen aC Region
-
Oct 2, 2025, 10:48Kanishk Kumar: TFPI Market Size - Advancing Hemostasis and Antithrombotic Therapy
-
Oct 2, 2025, 07:31Non-Invasive Management of Radial Artery Pseudoaneurysm
-
Oct 2, 2025, 07:28Mohamed Gamal: Rethinking The Standard of Care for Deep Vein Thrombosis Management
-
Oct 3, 2025, 14:00Quentin Van Thillo Shares His Latest Article on VWD: Grateful to Have Worked with Cedric Hermans
-
Oct 3, 2025, 13:40Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
-
Oct 3, 2025, 13:27Laura Haynes: This Was Such a Fun and Collaborative Project to Be a Part of!
-
Oct 3, 2025, 12:40Christian Pfrepper and Team's Letter on Emicizumab Plasma Concentration Measurment in EDTA plasma
-
Oct 3, 2025, 12:00Giuseppe Lippi and Colleagues on the Impact of Hemolysis on Coagulation Testing
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 1, 2025, 15:59Anirban Sen Gupta: Thrilled to share a great collaboration story in Nature Portfolio
-
Oct 3, 2025, 14:48Maha Othman - Elected as the Co-Lead for the Basic and Translational Research Platform at CanVECTOR Research Network
-
Oct 3, 2025, 14:41Maria Elisa Mancuso: A Real Pleasure to Participate in The Policy Roundtable on Future of Haemophilia Care in Egypt
-
Oct 2, 2025, 04:37Louise Bannon: Did You Know that 1 in 4 People Lose Their Lives to Blood Clot-Related Conditions?
-
Oct 1, 2025, 16:35World Thrombosis Day 2025․ 8 Ways to Take Control and Save Lives
-
Oct 1, 2025, 12:30World Stroke Academy "Antithrombotic Therapy for Atherosclerotic Stroke Prevention" Webinar is Now Available to Record